Objective: Traumatic brain injury (TBI) is a leading cause of disability and death worldwide, with an estimated 64-74 million cases annually. The current gold standard for diagnosis is a computed tomography (CT) scan, which has limitations such as access, cost, and radiation risk. Therefore, a simple, accessible, and safe diagnostic modality is needed, one of which is biomarker examination. This study aims to establish the relationship between blood levels of the biomarker ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1) and the severity of TBI based on the Glasgow Coma Scale (GCS) and Rotterdam CT score. Material and Methods: This observational analytic study with a cross-sectional design involved 41 samples aged 18-50 years who presented to the Emergency Department of Dr. Soetomo General Hospital, Surabaya, within 3-24 hours of the incident. UCH-L1 levels were measured from blood samples using the ELISA method, and the data on UCH-L1, GCS, and Rotterdam CT scores were analyzed with SPSS 29. Results: The mean UCH-L1 level was 0.522 ± 0.592, with a cutoff value of > 0.2057, indicating moderate to severe TBI if UCH-L1 levels exceeded 0.2057. Spearman's test and correlation coefficient analysis showed a strong relationship between UCH-L1 levels and Rotterdam CT score (p < 0.05), as well as between UCH-L1 levels and TBI severity based on GCS (p < 0.05). The cutoff value for Rotterdam CT score was > 2, indicating moderate to severe TBI if the score exceeded 2. Conclusion: Serum UCH-L1 levels are significantly associated with the severity of TBI based on GCS and Rotterdam CT score.
No takes yet. Share an insight, caveat, or question.
Manurung et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: